IRIS
POLONI, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.198
EU - Europa 4.880
AS - Asia 3.574
SA - Sud America 1.160
AF - Africa 248
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 12
AN - Antartide 1
Totale 19.092
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.074
SG - Singapore 1.255
IT - Italia 1.032
BR - Brasile 978
UA - Ucraina 782
CN - Cina 732
RU - Federazione Russa 568
DE - Germania 477
IE - Irlanda 477
SE - Svezia 436
HK - Hong Kong 376
VN - Vietnam 368
TR - Turchia 322
DK - Danimarca 288
FI - Finlandia 263
GB - Regno Unito 195
KR - Corea 163
FR - Francia 157
CI - Costa d'Avorio 114
IN - India 97
AR - Argentina 73
MA - Marocco 58
CA - Canada 54
MX - Messico 51
NL - Olanda 47
PL - Polonia 43
JP - Giappone 40
BD - Bangladesh 38
AT - Austria 36
IQ - Iraq 31
ZA - Sudafrica 31
EC - Ecuador 29
ID - Indonesia 29
BE - Belgio 22
UZ - Uzbekistan 21
ES - Italia 19
EU - Europa 19
VE - Venezuela 19
PK - Pakistan 18
PY - Paraguay 18
CO - Colombia 16
TN - Tunisia 14
AE - Emirati Arabi Uniti 13
PE - Perù 12
AU - Australia 11
AZ - Azerbaigian 8
KE - Kenya 8
IL - Israele 7
JO - Giordania 7
UY - Uruguay 7
CL - Cile 6
CZ - Repubblica Ceca 6
EG - Egitto 6
IR - Iran 6
KZ - Kazakistan 6
BG - Bulgaria 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
AL - Albania 4
BH - Bahrain 4
HN - Honduras 4
LT - Lituania 4
SA - Arabia Saudita 4
BZ - Belize 3
KG - Kirghizistan 3
KW - Kuwait 3
LB - Libano 3
MN - Mongolia 3
NP - Nepal 3
PH - Filippine 3
RO - Romania 3
SN - Senegal 3
ET - Etiopia 2
GA - Gabon 2
GT - Guatemala 2
MD - Moldavia 2
MT - Malta 2
MY - Malesia 2
PS - Palestinian Territory 2
PT - Portogallo 2
TW - Taiwan 2
AQ - Antartide 1
BJ - Benin 1
BO - Bolivia 1
CG - Congo 1
CR - Costa Rica 1
DM - Dominica 1
EE - Estonia 1
GY - Guiana 1
HR - Croazia 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MC - Monaco 1
ML - Mali 1
NE - Niger 1
NZ - Nuova Zelanda 1
Totale 19.086
Salva come PNG Salva come JPEG
Città #
Ashburn 908
Jacksonville 821
Singapore 761
Chandler 752
Fairfield 619
Dallas 582
Dublin 477
Boardman 467
Hong Kong 374
Des Moines 337
Wilmington 331
New York 307
Houston 250
Seattle 237
Woodbridge 209
Lawrence 182
Princeton 182
Beijing 179
Los Angeles 178
San Mateo 176
San Jose 164
Ho Chi Minh City 150
The Dalles 149
Cambridge 147
Ann Arbor 129
Hefei 125
Abidjan 114
Centro 112
Chicago 112
Moscow 111
Helsinki 82
Ancona 80
Hanoi 78
San Diego 78
Redmond 74
São Paulo 72
Munich 71
Buffalo 69
Turin 65
Milan 60
Rome 55
Marche 46
Salt Lake City 43
London 40
Pune 39
Denver 38
Guangzhou 36
Shanghai 35
Orem 34
Porto 33
Nuremberg 29
Warsaw 29
Norwalk 27
Pianella 27
Santa Clara 27
Turku 27
Washington 26
Lauterbourg 25
Stockholm 25
Brooklyn 24
Tokyo 24
Atlanta 22
Montreal 22
Phoenix 22
Rio de Janeiro 21
Vienna 20
Brussels 19
Chennai 19
Columbus 19
Haiphong 19
Poplar 19
Boston 18
Brasília 18
Naples 18
Tashkent 18
Belo Horizonte 17
Johannesburg 17
Elk Grove Village 16
Mexico City 16
Tampa 16
Amsterdam 14
Falconara Marittima 14
Toronto 14
Wuhan 14
Curitiba 13
Frankfurt am Main 13
Hangzhou 13
Porto Alegre 13
Ankara 12
Biên Hòa 12
Council Bluffs 12
Wuxi 12
Baghdad 11
Da Nang 11
Manchester 11
San Benedetto del Tronto 11
Campinas 10
Querétaro 10
San Francisco 10
Goiânia 9
Totale 11.655
Salva come PNG Salva come JPEG
Nome #
The Time Has Come for Targeted Therapies for AML: Lights and Shadows 355
Algoritmi diagnostico-terapeutici in Ematologia 289
Human white adipocytes convert into “rainbow” adipocytes in vitro 237
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 196
Human de-differentiated adipocytes show similar properties to bone marrow derived mesenchymal stem cells 189
Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome? 187
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment 177
Apoptotic mechanism activated by blue light and cisplatinum in cutaneous squamous cell carcinoma cells 177
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. 172
Conditioning regimen with beam plus amifostine for outpatient autologous stem cell tansplantation: feasibility and outcome in 97 lymphoma patients. 161
Adipocytes properties and crosstalk with immune system in obesity-related inflammation. 158
Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study. 157
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 156
Glial-like differentiation potential of human mature adipocytes 145
Efficacy and feasibility of high-dose cytarabine plus idarubicin and amifostine as induction schedule: a prospective observational study of 100 AML elderly patients 141
Human bone marrow adipocytes maintain the survival and differentiation of hematopoietic stem cells 141
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 139
Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. 139
A Combination of Lenalidomide and Rituximab (ReRi) As Salvage Therapy in Elderly Patients Affected By Diffuse Large B Cells (DLBCL) Lymphoma Relapsed and Refractory 138
Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin 137
A real life survey on erytropoietin alpha treatment in a cohort of 1049 low risk MDS patients: an italian MDS registry study 132
Azacitidine Treatment in High Risk Myelodysplastic Patients in Complete Haematological Remission Reverts Mesenchymal Stem Cells to a Normal Phenotype 132
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. 130
Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report 129
Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease 127
Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes. 127
The exosomal surface phenotype and inflamma-miR cargo correlate with MDS diagnosis 127
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. 127
The Exaggerated Collagen Expression in Gvhd-Fibroblasts Is Effectively Inhibited By Therapeutic Concentration of Nilotinib 126
Biosafety evidence for human dedifferentiated adipocytes 125
High predictive value of the revised international prognostic scoring system (IPSS-R): an external analysis of 646 patients from a multiregional italian MDS registry 124
Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis 124
Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. 122
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 121
Plasticity of human dedifferentiated adipocytes toward endothelial cells 121
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. 120
Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study 119
Hematologic reconstitution after PBPC autotransplantation:comparison between programmed-rate freezing and uncontrolled freezing at –80° 119
Cytokine expression profile of selected cell populations from patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation wih reduced conditioning. 119
LATE EFFECTS IN Hodgkin's POPULATION Treated BETWEEN 1980-2005 IN A SINGLE INSTITUTION 117
Gemtuzumab-Ozogamicin as Post-Consolidation Therapy In Elderly Patients with Acute Myeloid Leukemia: a Pilot Study 116
Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes 116
Bone marrow adipocytes support haematopoietic stem cell survival 115
Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate 114
Preventive Effects of Cardotoxicities By Liposomal Anthracyclines non Pegilated in 95 Perspective Patients Affected By Lymphoma and Monitored By Biomarkers and Ecocardiography 114
Human Mesenchymal Stem Cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion 114
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 113
A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure 113
Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. 113
MiR-422a promotes adipogenesis via MeCP2 downregulation in human bone marrow mesenchymal stem cells 113
Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes 112
Molecular and functional characterization of human bone marrow adipocytes 112
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 110
LA POSITIVITÀ DEL WT1 POST-INDUZIONE È UN IMPORTANTE FATTORE PROGNOSTICO PREDITTIVO DI RECIDIVA PRECOCE IN UNA CASISTICA DI 80 PAZIENTI AFFETTI DA LEUCEMIA ACUTA MIELOIDE 110
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia 109
Bone Marrow "Yellow" and "Red" Adipocytes: Good or Bad Cells? 107
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell trasplantation 106
Hematologic reconstitution after PBPC autotransplantation: comparison between programmed-rate freezing and uncontrolled-rate freezing at -80 degrees C 104
Screening of psychological distress in oncology and hematology department at Ospedali Riuniti Ancona 104
Targeting the immune system in MDS and MPN: Understanding the immunome and response to immunotherapy - Part 2 103
Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation 103
History and scientific production of clinica medica and clinica ematologica in ancona 103
A rare case of aCML associated with CNS involvement and with aggressive clinical course 103
Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS) 102
Identification of different adypocytes populations within human marrow microenvironment 102
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study 102
Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. 101
Patients with chronic extensive GvHD produce high levels of stimulatory auto-antibodies to the PDGF receptor: a new pathophysiological pathway of the disease progression 100
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems 100
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study 99
Mesenchymal stem cells of myelodysplastic syndromes show impaired hematopoietic support function and global DNA hypermethylation status 98
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study 97
mTOR and STAT3 Pathway Hyper-Activation is Associated with evated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment 96
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 95
Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow 95
AMIFOSTINE CAN REDUCE MUCOSAL DAMAGE AFTER HIGH-DOSE MELPHALANCONDITIONING FOR PERIPHERAL BLOOD PROGENITOR CELL AUTOTRANSPLANT: A RETROSPECTIVE STUDY. EFFECT OF AMIFOSTINE ON MUCOSITIS DURING AUTOLOGOUS PBPC TRANSPLANTATION 95
Long duration of response to azacitidine in MDS. Multicenter retrospective study of 36 patients 94
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality 94
Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. 93
DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype 93
CHANGES IN RPS14 EXPRESSION LEVELS DURING LENALIDOMIDE TREATMENT IN LOW- AND INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITH CHROMOSOME 5Q DELETION 92
Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome 91
Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience 90
TREATMENT WITH AZACITIDINE REVERSES MESENCHYMAL STEM CELLS DERIVED FROM HIGH RISK MYELODYSPLASTIC PATIENTS TO A NORMAL PHENOTYPE 90
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications 90
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study 89
Emopoiesi normale e mielodisplastica 88
VERY LOW TOXICITY AND GOOD QUALITY OF LIFE IN 48 ELDERLY PATIENTS AUTOTRANSPLANTED FOR HEMATOLOGICAL MALIGNANCIES: A SINGLE CENTER EXPERIENCE 88
Assessment and monitoring of CMV infection in patients receiving a reduced-intensity conditioning allogeneic transplant: comparison of antigenaemia assay with quantitative PCR 88
QUALITY OF LIFE ASSESSMENT IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROME 87
Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q) 87
A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study 87
TARGETED SEQUENCING ANALYSIS OF COMMONLY MUTATED GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA USING NGS: IMPACT AND CLINICAL IMPLICATIONS 87
OVEREXPRESSION OF CDKN2B IS ASSOCIATED WITH REDUCED PROLIFERATIVE POTENTIAL IN MESENCHYMAL STEM CELL FROM HIGH-RISK MYELODYSPLASTIC SYNDROME 87
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? 86
Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. 85
Post-transplant events Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders 85
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 84
Predictive value of post-induction and post-consolidation MRD: a comparison of multiparameter flow cytometry and WT1 RT-PCR techniques in 75 acute myeloid leukemia (AML) patients 84
Bone Marrow Adipose Tissue 83
Totale 12.010
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.794
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.794
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.260 0 0 0 0 0 0 266 117 313 177 263 124
2021/20221.467 72 351 26 90 10 80 68 111 91 131 136 301
2022/20232.479 225 241 208 188 155 516 2 120 584 10 184 46
2023/20241.626 228 49 87 233 254 371 42 35 5 56 33 233
2024/20253.608 357 318 141 61 131 101 305 101 859 262 338 634
2025/20265.060 630 737 687 1.054 892 658 402 0 0 0 0 0
Totale 19.598